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Abstract: The underlying ethos of dbGaP is that access to these data by secondary data 
analysts facilitates advancement of science. NIH has required that genome-wide association 
study data be deposited in the Database of Genotypes and Phenotypes (dbGaP) since 2003. 
In 2013, a proposed updated policy extended this requirement to next-generation sequencing 
data. However, recent literature and anecdotal reports suggest lingering logistical and 
ethical concerns about subject identifiability, informed consent, publication embargo 
enforcement, and difficulty in accessing dbGaP data. We surveyed the International  
Genetic Epidemiology Society (IGES) membership about their experiences. One hundred 
and seventy five (175) individuals completed the survey, a response rate of 27%.  
Of respondents who received data from dbGaP (43%), only 32% perceived the application 
process as easy but most (75%) received data within five months. Remaining challenges 
include difficulty in identifying an institutional signing official and an overlong application 
process. Only 24% of respondents had contributed data to dbGaP. Of these, 31% reported 
local IRB restrictions on data release; an additional 15% had to reconsent study 
participants before depositing data. The majority of respondents (56%) disagreed that the 
publication embargo period was sufficient. In response, we recommend longer embargo 
periods and use of varied data-sharing models rather than a one-size-fits-all approach.  
Keywords: data sharing; identifiability; GWAS; ELSI; ethics; publication  
embargo; collaboration  
 
1. Introduction 
In 2003, the National Institutes of Health (NIH) implemented a data sharing policy requiring data 
obtained in NIH-supported or conducted genome-wide association studies (GWAS) to be posted to the 
database of Genotypes and Phenotypes (dbGaP) or a similar database (NOT-OD-07-088,) [1]. In 2013, 
the policy was updated to cover the technological advances in next-generation sequencing so that  
whole-exome and whole-genome sequencing studies would also be required to share their data through 
dbGaP or similar databases. There are several potential advantages of such a data sharing policy. First, 
open access to such complex data reduces barriers and may more rapidly advance science and creativity, 
leading to novel discoveries [2]. Second, data sharing maximizes the return on the public investment in 
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generating such data, an especially pertinent consideration if one believes that society owns publicly 
funded data [3].  
These advantages are counter-balanced by practical and ethical concerns in the implementation of 
this data sharing policy, and in some cases the NIH has already responded to address issues raised by 
the research community. One issue is that specific individuals can be identified based on genomic data 
when combined with other publicly available data resources [4–6]. Another study showed that a 
surname can be linked with an individual’s genomic data using genealogical databases for descendants 
of the Latter-Day Saints founders [7]. Indeed, the U.S. Department of Health and Human Services has 
proposed to update the common rule to specifically define biospecimens and genetic data as 
identifiable (docket ID number HHS-OPHS-2011-0005; Advance Notice of Proposed Rulemaking 
(ANPRM) regarding Human Subject Research Protections). A second issue is that an individuals’ risk 
for a specific disease can still be inferred even if known risk allele data is removed. For example, 
based on the linkage disequilibrium structure of APOE, as well as available HapMap data, one could 
accurately predict Alzheimer’s disease risk for an individual even after removal of the individual’s 
APOE genotypes from the analysis [8]. Based on these findings, allele frequencies and other summarized 
data were no longer publicly posted on the NIH site. More recently, it was shown that a number of 
individuals from the Center for Study of Human Polymorphisms (CEPH) family collection whose 
genomes were sequenced as part of the 1000 Genomes project could be identified [9].  
Other concerns with the implementation of the data sharing policy have not yet been fully 
addressed. First, although the policy allows waivers to the requirement for submission of data to 
dbGaP, in practice the implementation of this policy occurs at the institute level, which could allow 
inconsistency in how waivers are managed or approved. Much of the need for waivers stems from the  
re-use of DNA samples for genetic studies that were collected prior to the discussion of identifiability 
and shared databases; thus, appropriate language about possible risks or benefits to the 
donors/participants was never included in informed consent forms. Second, a subject’s option to 
withdraw from a study is of limited effectiveness once the data is shared in public, as that data has 
already been distributed, often cannot be recalled, and therefore may be used for further analysis even 
against the will of participants [10]. Third, a publication embargo period was established on many, but 
not all, data submitted to dbGaP to recognize the intellectual contributions of the data submitters in 
establishing the data resource and provide them with the first opportunity for publication; however, a 
violation of the publication embargo has already occurred [11]. In that case, the authors were 
reprimanded by both their institution and the NIH, and although the publication was officially retracted 
by the journal, it remains available online. Few studies have explored the perceived practical and 
ethical concerns of researchers regarding data sharing from GWAS, and whether those concerns 
represent significant barriers to the success of dbGaP and other methods of data sharing. To that end, 
we conducted a survey of the membership of the International Genetic Epidemiology Society (IGES) 
to explore the experiences of researchers with dbGaP. IGES is a scientific society concerned with ―the 
study of genetic components in complex biological phenomena‖ [12]. IGES members include 
geneticists, epidemiologists, statisticians, mathematicians, biologists, related biomedical researchers 
and students interested in research on the genetic basis of diseases, complex traits, and their risk 
factors. This survey population may provide generalizable insights for several reasons. First, the IGES 
membership is involved in human genetic research and includes scientists who have contributed data 
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to dbGaP. Second, IGES members, especially those who are developing novel statistical methods and 
genetic epidemiological techniques, are among the researchers most interested in obtaining data from 
dbGaP. Finally, the practical barriers and perceived ethical challenges experienced by IGES members 
with dbGaP use for genome-wide association (GWA) data have relevance for future sharing of whole 
exome (WES) and whole genome sequencing (WGS) data.  
2. Experimental Section  
2.1. Survey Design and Implementation 
Members of the IGES Ethical, Legal, and Social Issues (ELSI) committee designed the survey 
instrument (supplemental materials). The committee is a multidisciplinary group generally interested 
in current ELSI issues as they relate to genetic epidemiologists. Committee members come from a 
variety of backgrounds and have varied research interests ranging from biology, medicine, statistical 
genetics, and epidemiology, to bio-ethical theory and law. Questions, both multiple choice and  
free-text, covered domains including demographics, past application for research funding, contribution 
of data to dbGaP, access of data through dbGaP and other similar databases, and avoidance of the data 
sharing policy. We implemented the survey, containing 44 questions, on SurveyMonkey
®
 [13]. 
Members of the IGES ELSI committee pilot tested the survey to check the skip patterns to the questions 
and ease of use; however, we did not pilot test the survey with external reviewers to assess the readability 
or comprehension of the survey questions. All IGES members were invited to complete the survey by 
email through the IGES membership listserver. We sent two reminder emails, as well as a post to the 
―Friends of IGES‖ Facebook page. No incentive was given for participation in the survey, and no 
identifying information (e.g., IP address) was obtained from the survey participants. The survey was 
open for response from October to November of 2010. 
2.2. Data Analysis 
We downloaded a dataset containing all participant response data from SurveyMonkey as an Excel 
file. We computed descriptive statistics and statistical analyses using SPSS version 19 (IBM Corp. 
Armonk, NY, USA)). Percentages are reported based on the number of valid responses for each 
question. Analyses of categorical data were conducted using chi-square statistics. Eight questions were 
open-ended; responses for those could be entered into a box that could contain a brief paragraph. 
Eleven questions provided an ―other‖ category as a response; the respondent could then specify an 
alternative response. We analyzed data from open-ended questions by looking for common themes. 
Responses were first separated into the two major thematic categories that corresponded to either 
common practical or ethical concerns. These responses were then further analyzed to identify more 
specific areas of concern. 
3. Results and Discussion 
A total of 187 individuals started the survey; 175 out of 643 IGES members completed it (Table 1), 
resulting in a response rate of 27%. Most of the survey respondents (77%) were ―Regular‖ (i.e.,  
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not student) IGES members. The distribution of survey respondents by continent was roughly 
equivalent to the overall distribution of IGES membership (Table 1).  
Most of the survey respondents work in academic or university environments (Table 2). There was 
a fairly uniform distribution of respondents across time spent in their current position, with the 
exception that fewer people had spent 11 to 15 years at their current position. Most of the faculty 
respondents had applied to the NIH for research funding (83%), regardless of whether they worked in 
North America (Table 2).  
Table 1. Demographics of survey respondents compared to overall IGES membership. 
 Survey Respondents a
 
IGES Overall Membership 
a 
Students 33 (18%) 146 (23%) 
Regular  147 (82%) 497 (77%) 
Total 175 643 





Canada 37 (6%) 
Europe 39 (21%) 123 (19%) 
Australia, New Zealand, and Other 9 (5%) 55 (8%) 
a Data shown as absolute frequencies (% of total). b These two categories are combined because the survey 
only asked whether respondents worked in North America, so that data were not identifiable. 
Table 2. Survey respondents’ position characteristics. 
Characteristic N (%) 
Type of organization  
Academic or university 129 (72%) 
Government agency 17 (9%) 
Hospital 11 (6%) 
Research Institute 22 (12%) 
Industry 1 (0.5%) 
Length of time in current position  
< 3 years 52 (29%) 
3 to 5 years 37 (21%) 
6 to 10 years 41 (23%) 
11 to 15 years 15 (8%) 
 > 15 years 35 (19%) 
3.1. Data Access 
Of all respondents, 43% (N = 80) reported accessing data from dbGaP at least once (Table 3).  
When asked, ―How long did it take to complete the application and receive the data the first time you 
applied?‖, 37.5% (N = 30) stated it took less than 3 months, and an additional 37.5% (N = 30) indicated 
that it took 3–4 months. Among those who reported applying for data more than once (N = 30), 
responses to the question, ―How long did it take to complete the application and receive the data the 
most recent time you applied?‖ did not differ noticeably. When asked how much they agreed/disagreed 
that the process of requesting data from dbGaP was easy, many respondents (32%) agreed.  
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The duration of time it took to complete application and receive the data was associated with whether 
the respondent agreed that the dbGaP application process was perceived as easy (p = 0.015).  
We also asked what sort of ethics board approval, if any, was required when accessing dbGaP data. 
Sixteen percent (N = 13) of individuals reported full ethics board approval, 38% (N = 30) reported an 
expedited review, 20% (N = 16) reported that their institution waived the requirement for ethics board 
approval, and 15% (N = 12) reported that their institution did not require ethics board approval  
(Table 4). Thus, ethics board approval requirements were widely variable across institutions; this did 
not differ significantly by the type of institution (p = 0.153) or by continent (p = 0.312) (data not 
shown). The type of IRB approval needed was not associated with whether the respondent agreed that 
the dbGaP application process was perceived as easy (p = 0.239).  











Missing / No 
Response 
The process for 
requesting data from 
dbGaP was easy 
2 (3) 23 (29) 25 (31) 14 (18) 9 (11) 7 (9) 
It was easy to find a 
signing official 
29 (36) 23 (29) 7 (9) 7 (9) 1 (1) 13 (16) 
a Numbers are absolute frequencies (%); b Only individuals who reported requesting data from dbGaP 
responded to this question (N = 80).  
Table 4. IRB application experience for individuals requesting dbGaP data. 
Response N (%) a 
Yes, I had to go through full-board review 13 (16) 
Yes, I had to go through an expedited IRB (or equivalent) review 30 (38) 
No, the IRB (or equivalent) waived the requirement for approval, or the study 
was considered exempt 
16 (20) 
No, my Institution does not require me to apply for IRB (or equivalent) 
approval to obtain and analyze data from dbGaP 
12 (15) 
Missing / no response 9 (11) 
a Data shown as (absolute) frequencies (%), N = 80. 
An ―institutional official‖ needs to sign a researcher’s application for dbGaP data, a concept that 
may not be well-defined for organizations that do not receive funding from NIH. Most individuals 
(65%) either agreed or strongly agreed that it was easy to identify a signing official. However, the title 
of the signing official varied widely. In the free-text field where respondents listed the title of the 
signing official, 12 individuals reported a title of someone in a research administration office,  
six individuals reported the title of an academic head or scientific director, three individuals reported a 
―director‖ position that did not appear to fit into a research office or academic head, and two 
individuals reported getting the signature of the president of the university. The ease of identifying a 
signing official differed significantly by type of institution, with more people in research institutes 
reporting difficulty with identifying the signing official (p = 0.003, data not shown). This issue was 
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also associated with continent, with more Europeans reporting problems than North Americans  
(p = 0.029, data not shown); five European respondents (36%) either agreed or strongly agreed that it 
was difficult to find a signing official, and four individuals at research institutes (44%) also agreed or 
strongly agreed it was difficult to find a signing official. The ease of identifying a signing official was 
associated with whether the respondent agreed that the dbGaP application process was perceived as 
easy (p = 0.005).  
Only 19% of individuals (N = 15) reported contacting the original data contributors regarding 
questions about the data. 
3.2. Data Contributors 
Twenty-four percent (N = 45) of all respondents reported being the principal investigator or  
co-investigator on a study that contributed data to dbGaP. We note that dbGaP submission requires the 
local IRB to certify consistency with laws and regulations, which can vary by state or country,  
and with the content necessary to be provided in informed consent documents, which can vary by 
study as well as by state or country. Of the respondents who contributed data to dbGaP, 31% (N = 14) 
reported local IRB restrictions on data release, and 31% (N = 14) reported that they had to reconsent 
study participants (seven individuals answered ―yes‖ to both questions). Of the individuals who did 
reconsent their study participants, at least 32% did not inform them of the risk of being identified from 
genotype or phenotype data (Table 5).  
Table 5. Information about depositing data to dbGaP from 45 responders. 
Questions and Responses N (%) 
a
 
For how many studies have you deposited data into dbGaP?   
 1 28 (62) 
 2 12 (27) 
 3 1 (2) 
 5 2 (4) 
 Missing / no response 2 (4) 
For any of the studies that you contributed to dbGaP, did your IRB  
(or equivalent) put any restrictions on data release? 
 
 Yes 14 (31) 
 No 21 (47) 
 Not sure 9 (20) 
 Missing / no response 1 (2) 
For any of the studies that you contributed to dbGaP, did you reconsent the 
research participants in order to deposit the data on dbGaP 
 
 Yes 14 (31) 
 No 24 (53) 
 Not sure 6 (13) 
 Missing / no response 1 (2) 
When you reconsented individuals, did you inform individuals about the 




 Yes 6 (43) 
 No 3 (21) 
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Table 5. Cont. 
Questions and Responses N (%) 
a
 
 Not sure 5 (36) 
How much do you agree with the following statement: The embargo period 
was sufficient to perform the analyses that I wanted to do? 
 
 Strongly agree 1 (2) 
 Agree 9 (20) 
Disagree 12 (27) 
 Strongly disagree 13 (29) 
 Undecided 6 (13) 
 Too early to determine 3 (7) 
 Missing / no response 1 (2) 
a
 Denominator for this question is N=14, the number of individuals who reconsented their subjects; b Data 
shown as (absolute) frequencies (%) 
While seven individuals requested a waiver from submitting data to dbGaP, three of these 
individuals did not get the waiver granted. The four successful requests for waivers included the 
following justifications: a foreign study population (N = 1), ―no consent‖ or ―not able to reconsent‖  
(N = 2), and ―sensitive topic‖ (N = 1). The three unsuccessful waiver requests provided justifications 
that included ―would require reconsent‖ (N = 2) and ―participating American Indian tribes would not 
agree to broad data sharing‖ (N = 1).  
Our final question for data contributors was whether the publication embargo period was sufficient 
to perform the desired analyses. The majority of respondents (56%) either disagreed or strongly 
disagreed that the embargo period was sufficient (Table 5). Two individuals reported in a free-text 
field that data they had submitted to dbGaP, had been downloaded and analyzed by another group and 
the findings published before the embargo period was over.  
3.3. Alternatives to Depositing Data in dbGaP 
Next, we asked a series of questions to get a sense of whether the current data sharing policy limits 
opportunities for research, and, if so, what are the perceived barriers. Eleven percent of all respondents 
(N = 21) reported applying for funding elsewhere to avoid the NIH data sharing policy. Fourteen 
percent (N = 26) of individuals decided not to apply for NIH funding specifically because of the data 
sharing policy. Fourteen people answered ―yes‖ to both questions. Several reasons were given for this 
(Table 6). The most prevalent response was that the consent form or local IRB would not allow this 
type of data sharing (N = 16), or it would be ―not legally possible because of requirements in country‖ 
(N = 12); six people responded that they ―do not trust the system of data sharing‖.  





It would not be legally possible to deposit the data in dbGaP according to country’s 
(or institutional) requirements 
13 
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The procedure was too complicated 3 
The consent form would not allow broad data sharing 16 
Did not trust system of data sharing 6 
The data sharing policy is ―not in agreement with my personal ethical opinions‖ 1 
Subjects deceased and cannot be reconsented 1 
Inability to require IRB approval by data requestors 1 
Vulnerable population 1 
Data collected from other countries 1 
Social responsibility 1 
* Respondents may have selected more than one relevant response, so only absolute frequencies are shown. 
3.4. Future Implications 
We asked whether respondents foresee additional problems with depositing/sharing WGS data;  
only 32% (N = 60) agreed. Respondents were then given the opportunity to describe their own 
perceptions of these specific problems through an open-ended question. These qualitative responses 
are not meant to be generalized or representative, but do provide some insight into the types of 
concerns researchers may have about interfacing with dbGaP and other large genomic databases. 
Responses to this question fell into two primary thematic categories: practical barriers associated with 
the management and ―usability‖ of the database, and ethical concerns regarding contributing data and 
the future use of DNA and RNA sequence data. However, within each of these categories, respondents 
were varied in their actual concerns.  
First, with regard to the practical challenges of dbGaP, some respondents were skeptical of the 
sustainability of dbGaP itself given concerns about the ability of the system to store and manage such 
large datasets while making them easily accessible to researchers. Others expressed more specific 
concerns about the ability of researchers to interface with dbGaP for purposes of both transferring data 
to the database and enabling researchers to access the data for future research. One researcher wrote 
that (s)he perceived ―data transferral with these large datasets will be highly problematic‖ while 
another voiced concerns over the amount of ―pre-processing and standardization‖ needed for large 
datasets. Additionally, respondents expressed concerns regarding the utilization of data in dbGaP for 
future studies, including a number of researchers that indicated apprehension about the time required to 
download larger datasets and others who felt that the user interface was hard to use or ―cumbersome‖. 
Lastly, a few respondents said that they would question the quality of raw DNA or RNA sequence data 
from dbGaP in light of their concerns about the ability of dbGaP to effectively manage and usefully 
transfer to researchers the large volume of information associated with sequence data.  
In addition to these practical issues, respondents identified ethical and social implications of 
contributing and using data associated with dbGaP. Three interconnected concerns were mentioned:  
(i) the problem of increased identifiability of study participants, (ii) the impact of increased identifiability 
on the consent process, and (iii) potential difficulties in subject recruitment due to (i) and (ii).  
The problem of identifiability is amplified by the ability to mine DNA sequence data for  
―rare variants‖, potentially making an individual or families more identifiable. One respondent thought 
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the contribution of sequence data to dbGaP would compromise the ability of researchers to assure the 
privacy and confidentiality of study participants, while others felt that participants may worry about 
their genetic data being used for the identification of deleterious mutations without their knowledge  
or permission.  
An increased risk of identifiability (and concomitant loss of confidentiality) can be expected to have 
an impact on the consent process. One respondent asked, ―How is the consenting of patients for this 
type of data release going to be handled? Will a general data release statement be sufficient as it was 
for SNPs? How do we define informed consent?‖ Another individual discussed fears that contributing 
whole genome or exome sequence data to dbGaP presents ―deeper issues of identification‖ and raises 
questions as to ―whether we can truly adequately consent people for this type of data sharing‖.  
Lastly, one researcher expressed a further worry that requirements to contribute data might hurt 
subject recruitment due to a ―possible reluctance of some to participate in studies‖. If the sharing 
requirement for sequence data has a chilling effect on subject recruitment, it would undermine the 
potential benefits expected from the policy. 
4. Conclusions  
In summary, many respondents to our survey (34%) agreed that they perceive the application 
process for dbGaP data access as easy and 75% were able to receive data in less than five months.  
The considerable effort put into the development of the dbGaP system [11] has resulted in a few 
remaining challenges. These opportunities for improvement of the system, including simplifying the 
approach to identify a ―signing official‖ and management of large datafiles, are modest when 
compared with the challenges of initiating new data collection, which can take years. On the other 
hand, researchers who contribute data to dbGaP face many challenges, primarily local IRB restrictions, 
the need to reconsent individuals and inform them about potential risks of identifiability, and the short 
length of the publication embargo period. Significant opportunity for improvement in the implementation 
of the NIH data sharing policy is still possible from the perspective of data contributors. Further, a mixed 
approach to data sharing models—including consortiums and workshops—may also alleviate some of 
these challenges. 
4.1. Issues for dbGaP Access and Use 
The race to publish on one’s own data as it relates to the publication embargo remains an issue.  
In our relatively small dataset, two individuals reported that data recipients from dbGaP published 
before the embargo period was over. As stated by Kaye et al. [2], ―no one wants to be part of a system 
in which they feel that someone else can take advantage of their contributions.‖ Furthermore,  
Kaye et al. [2] argue that working against deadlines is not consistent with a productive climate.  
On the other hand, others argue that without a deadline, researchers hold their data indefinitely without 
analyzing and publishing, so a deadline is a strong motivating factor. We recommend that the 
publication embargo policy be reviewed to enable more time for the data contributors to analyze and 
publish on their own data, which would provide greater protection and recognition of the intellectual 
contributions of the data contributors and their expertise with the dataset. Additionally, we recommend 
that enforcing the publication embargo be a shared responsibility between data requestors and others—
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journal reviewers, journal editors, and the NIH—who can find proactive solutions to identify potential 
violations before they occur.  
In our study, a minority of dbGaP users (<20%) contacted the data collectors, though this was 
encouraged by the coordinators of dbGaP, as evidenced by the prominent publication of contributors’ 
contact information. Krawczak et al. [14] point out that the bottleneck in generating high quality 
genetic epidemiological data is mostly in the recruitment and phenotyping of subjects, not in the 
genotyping. Those who collected the data may be aware of subtleties that can improve analyses or 
interpretation. Thus, we encourage increased interaction with the data collectors and formal 
recognition of their efforts. Also, we encourage data collectors to be responsive to the collaborative 
attempts of secondary data analysts. Depending on the extent of collaboration with the data collectors, 
recognition of their efforts may be made via co-authorship or in the acknowledgments section of the 
paper. A recent editorial published in Nature Genetics also suggested the use of citable data 
management plans as another method to acknowledge the data collectors [15]. 
4.2. Ethical Implications for Access and Contribution 
We observed a great deal of variability in local IRB requirements for receiving dbGaP data.  
One possibility is that we observe this variation because there are different requirements for ethics 
board approval depending on the dbGaP dataset, and it is a limitation of our survey that we did not 
distinguish which dbGaP datasets the survey respondents had requested. However, this variation 
among respondents regarding their IRB requirements for dbGaP access may be concerning for 
contributors to dbGaP, because it may imply variability among IRBs in the understanding of genetic 
databases and the implications for human subject protection. As recently noted by OHRP in the 
Advanced Notice of Proposed Rule Making (ANPRM) for revision to the Common Rule [16],  
this variation is a broad concern, and is not limited to genetic research. McGuire and Gibbs [17] state 
that, in their experience, the consent process for most disease-specific genetic research is not protective 
for broad genomic data sharing because privacy risks are not stated. McWilliams et al. [18] found that 
IRB review of genetic epidemiology studies was inconsistent across local IRBs. More recently,  
Lemke et al. [19] found wide diversity among IRB members in the specific ethical implications 
inherent in genetic data, such as the risk of identifiability, the need for reconsent, clarity in NIH data 
sharing guidelines, likelihood of individuals being identified from genetic data, and likeliness of harm. 
The issues of re-consent and warning participants of the risks of identifiability are challenging because 
these risks are unknown. As pointed out by Kaye et al. [2], ethics committees cannot exert their 
mandates on recipients of data from other institutions. A potential solution for dbGaP is to require data 
requestors to obtain IRB approval from the IRB where the data were collected through Data  
Use Limitations [20]. 
4.3. The Consortium Model 
A complimentary model to public data sharing, which has been quite successful, is the formation of 
large consortia in which data from different projects are combined, and a variety of researchers with 
different expertise in aspects of phenotyping and methodology collaborate to jointly analyze their data. 
The consortium data sharing model may be particularly advantageous in situations where potential data 
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contributors experience limitations because of local IRB restrictions or a need to reconsent study 
participants. Often, data are meta-analyzed in order to gain statistical power, and numerous consortia 
have published on novel loci identified using this model of data sharing. Examples include the  
CHARGE consortium [21], the CARe consortium [22,23], the Alzheimer Disease Genetics Consortium  
(ADGC) [24], CGASP [25], other smoking consortia [26,27], LLAS1 and LLAS2 [28,29], and the 
Electronic Medical Records and GEnomics (eMERGE) consortium [30].  
Data are not shared as widely under this model, and large consortia have challenges, some of which 
are in common with the challenges of data sharing through dbGaP. The experiences of consortia with 
their internal data sharing and authorship policies may vary widely, and enforcement of those policies 
may be delicate because of relationships among collaborators. Often (but not always) large consortia 
do not have dedicated research funding to support additional data analysts, data coordinating centers, 
or common genotyping core facilities. The activities of the consortium must be conducted using 
resources on existing, potentially smaller-budget grants. Data transfer within consortia may also have 
logistical difficulties, such as the amount of time for transferring large scale sequencing data or  
the need for pre-processing and standardization, that are similar to the challenges for data sharing 
through dbGaP. 
However, there are advantages of the consortium model. First, the research teams are working 
together, so any questions about how the data were collected or how phenotypes were defined can be 
resolved. Second, collaborating groups work directly with the IRBs of the institutions where the data 
were collected. In contrast, dbGaP data requestors frequently obtain IRB approval from their local IRB 
rather than the IRB responsible for the approval of the study for collecting data. Consortia deal with 
this issue directly by writing memoranda of understanding, and additionally, investigators add each 
other to their IRB protocols.. Third, as discussed above, there is direct acknowledgment of the data 
collectors via co-authorship. One recommendation to further enhance collaboration in the same spirit 
of the NIH data sharing policy is to expand research funding for consortia to support the activities of 
research teams. Indeed, some survey respondents implied support for this model when answering the 
open-ended questions throughout the survey. Further, the consortium model could be strengthened by 
developing a mechanism, perhaps through dbGaP, to publicize information about existing consortia so 
that interested researchers could contact members of those consortia to develop collaboration.  
One reason for the development of dbGaP was to make data available for the purposes of 
methodology development. The Genetic Analysis Workshop (GAW) is another enormously successful 
model to stimulate collaboration among scientists interested in methodological questions. The GAW 
addresses questions about the robustness of analytical approaches for genetic data and serves as a 
forum for discussing new methods of analysis. The GAW has been ongoing since 1982 [31], and is 
supported through a grant from the National Institute of General Medical Sciences. The most recent 
GAW meeting in 2012 included 184 participants from 14 countries [32]. For each meeting, specific 
datasets are selected for analysis by an advisory committee, and are distributed to interested 
researchers about six months prior to the meeting. The workshop paradigm is particularly suited to 
advances in methodology development since all individuals are working on the same dataset(s), 
focusing on the same set of methodological questions, and meeting together to discuss results and learn 
from one another. Thus, we recommend additional funding for similar workshops.  
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4.4. Implications for Future Studies 
The issues that have been identified for sharing GWAS data through dbGaP may be amplified when 
sharing WGS data. WGS datafiles are vastly larger than those from GWAS. Genetic epidemiologists 
have encountered problems in downloading 1000 Genomes data, and such problems will be intensified 
many-fold with deep coverage sequence data. Thus, effective sharing of sequence data may be limited 
to individuals with considerable computational resources, although this may change as computational 
technology advances. In addition, there is an ongoing debate about the identifiability of subjects from 
GWAS, WES or WGS data, and these concerns were raised by our survey respondents. Malin et al. [33] 
detail the conditions for identifiability, which include whether the data are ―distinguishing‖ (genome 
data fall into this category) and the availability of a ―naming resource‖. Thus, the risks of 
identifiability may vary widely in human genetic studies and should be considered as these large 
datasets are made available. Furthermore, while clinically relevant information in GWAS data is 
limited to sex chromosome anomalies and a small number of disease risk SNPs [34], an added 
complexity of WGS data is the significantly greater potential of discovering ―incidental findings‖ of 
well-characterized risk variants [2,34–36]. If in the original consent form the duty to report incidental 
findings is mentioned, complying with this obligation may be challenging when secondary data 
analysts make these discoveries. As the technology to create WGS data moves forward, there will be a 
great need to develop statistical methodologies to analyze these data, so the motivation to share these 
data is high in spite of the logistical concerns. Further discussion of the ethical implications of 
identifiability and incidental findings must precede the development of policies for sharing WGS data.  
4.5. Limitations 
There are some limitations of this survey and its analysis. First, the survey was only administered to 
IGES members, and thus may not be generalizable to all users of dbGaP. Geneticists with other 
specializations also have accessed or contributed to dbGaP, and so our results may not reflect their 
experiences. Second, the response rate to the survey was quite low (27% of IGES members), and it is 
unknown why a larger percentage of the IGES membership did not respond to the survey. Because of 
the low response rate, the study findings are susceptible to bias if individuals with particularly good or 
bad experiences preferentially responded to the survey. Also, we did not pilot test the survey questions 
with external reviewers to assess the readability or comprehension of the survey questions, so we do 
not know whether or not some respondents had difficulties responding to the questions. Finally, there 
are a number of topics that were not included in our survey, such as experiences with consortia, how 
long it takes to complete specific aspects of the application process including identifying the signing 
official, how data recipients used the data, and what were the perceived benefits of the policy. 
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